Turning Innovation Into Execution In CNS Trials

By Dr. Rachna Saralkar, MD, MS, Principal Investigator, Flourish Research

CNS and mental health research is entering a new phase—one defined less by shiny technology and more by disciplined operational design. At SCOPE 2026, leaders across the field emphasized that future progress hinges on aligning protocols with real-world clinical environments, supporting site teams, and embedding patient experience into every stage of planning.

A key theme was iteration: meaningful innovation requires structured testing, honest evaluation, and the willingness to adjust before a study ever reaches a site. Approaches like sponsor-led mock visits and site‑level “patient zero” run-throughs are emerging as powerful tools for uncovering workflow barriers early, strengthening feasibility, and reducing downstream friction.

The conversation also highlighted expanded investigator models, including the growing contribution of PAs who often provide consistent, hands-on oversight in CNS trials. Patient engagement is likewise becoming non‑negotiable, moving from advisory boards to one‑on‑one insight that shapes protocol DNA. And as psychedelic research grows, safety frameworks must adapt to capture both typical and atypical perceptual shifts responsibly.

Together, these perspectives signal a pivotal shift: the future of mental health trials will be built on practical collaboration, strong operational fundamentals, and designs that reflect the realities of care.